The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients

Nuclear Medicine Communications

Volumn 31, Issue 7, 2010, Pages 637-645

  Yen, Ruoh Fang ^a   Chen, Chih Yu ^a,b   Cheng, Mei Fang ^a   Wu, Yen Wen ^a   Shiau, Yu Chien ^b   Wu, Karl ^a,b   Hong, Ruey Long ^a   Yu, Chong Jen ^a   Wang, Kao Lun ^b   Yang, Rong Sen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Bone metastases; F 18 NaF PET CT; Hepatocellular carcinoma; Survival; Tc 99m methylene diphosphonate bone scintigraphy

Indexed keywords

FLUORIDE SODIUM; MEDRONATE TECHNETIUM TC 99M; SODIUM FLUORIDE F 18; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MALE; OSTEOLYSIS; PROGNOSIS; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TAIWAN;

ADULT; AGED; BONE AND BONES; BONE NEOPLASMS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORINE RADIOISOTOPES; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; SODIUM FLUORIDE; SURVIVAL ANALYSIS; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953359870     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283399120     Document Type: Article

References (36)

1. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma conclusions of the barcelona-2000 EASL conference. J Hepatol 2001; 35:421-430.
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35:S72-S78.
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139:817-823.
4. Segawa T, Tsuchiya R, Furui J, Izawa K, Tsunoda T, Kanematsu T. Operative results in 143 patients with hepatocellular carcinoma. World J Surg 1993; 17:663-668.
5. Castellano L, Calandra M, Del Vecchio Blanco C, De Sio I. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. J Hepatol 1997; 27:862-870.
6. Verslype C, Van Cutsem E, Discato M, Arber N, Berlin JD, Cunningham D, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from 10th world congress on gastrointestinal cancer, Barcelona, 2008. Ann Oncol 2009; 20:vii1-vii6.
7. El-Serag HB, Marrero JA, Rudolph L, Rajender Reddy K. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134:1752-1763.
8. Fukutomi M, Yokota M, Chuman H, Harada H, Zaitsu Y, Funakoshi A, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2001; 13:1083-1088.
9. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K, et al. Pathology of hepatocellular carcinoma in Japan. 232 consecutive cases autopsied in ten years. Cancer 1983; 51:863-877.
10. Subramanian G, McAfee JG. A new complex of 99mTc for skeletal imaging. Radiology 1971; 99:192-196.
11. Algra PR, Bloem JL, Tissing H, Falke THM, Arndt JW, Verboom LJ. Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radio Graphics 1991; 11:219-232.
12. Fujimoto R, Higashi T, Nakamoto Y, Hara T, Lyshchik A, Ishizu K, et al. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med 2006; 20:399-408.
13. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000; 20:2189-2192.
14. Kuhlman JE, Fishman EK, Leichner PK, Magid D, Order SE, Siegelman SS. Skeletal metastases from hepatoma: frequency, distribution, and radiographic features. Radiology 1986; 160:175-178.
15. He J, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 2009; 115:2710-2720.
16. Nagaoka S, Itano S, Ishibashi M, Torimura T, Baba K, Akiyoshi J, et al. Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int 2006; 26:781-788.
17. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962; 3:332-334.
18. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008; 49:68-78.
19. Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999; 40:1623-1629.
20. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999; 17:2381-2389.
21. Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42:1800-1804.
22. Krasnow AZ, Hellman RS, Timins ME, Collier D, Anderson T, Isitman AT. Diagnostic bone scanning in oncology. Semin Nucl Med 1997; 27:107-141.
23. Krüger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009; 36:1807-1812.
24. Yamashita K, Denno K, Ueda T, Komatsubara Y, Kotake T, Usami M, et al. Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 1993; 71:1297-1302.
25. Han LJ, Au-Yong TK, Tong WCM, Chu KS, Szeto LT,Wong CP. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med 1998; 25:635-638.
26. Reinartz P, Schaffeldt J, Sabri O, Zimny M, Nowak B, Ostwald E, et al. Benign versus malignant osseous lesions in the lumbar vertebrae: differentiation by means of bone SPET. Eur J Nucl Med 2000; 27:721-726.
27. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005; 35:135-142.
28. Nakamoto Y, Cohade C, Tatsumi M, Hammoud D,Wahl RL. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology 2005; 237:627-634.
29. Okusaka T, Okada S, Ishii H, Nose H, Nagahama H, Nakasuka H, et al. Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology 1997; 44:251-257. (Pubitemid 27096048)
30. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13:414-420.
31. Satya Suresh Attili V, Govind Babu K, Lokanatha D, Bapsy PP, Ramachandra C, Rajshekar H. Bone metastasis in hepatocellular carcinoma: need for reappraisal of treatment. J Cancer Res Ther 2008; 4:93-94.
32. Maccauro G, Muratori E, Sgambato A, Liuzza F, Esposito M, Grieco A, et al. Bone metastasis in hepatocellular carcinoma. A report of five cases and a review of the literature. Chir Organi Mov 2005; 90:297-302.
33. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47:287-297.
34. Horger M, Eschmann SM, Pfannenberg C, Vonthein R, Besenfelder H, Claussen CD, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR 2004; 183:655-661.
35. Schillaci O, Danieli R, Manni C, Simonetti G. Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation? Nucl Med Commun 2004; 25:705-710.
36. Hawkins RA, Choi Y, Huang SV, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 1992; 33:633-642.